Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
SWITCH
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
- NCT06649331 ↗
- Recruiting
- Fudan University
- Focused
We haven't built an HCP commentary report on SWITCH (SHR-A1811, SHR-A1921 and 6 more in Advanced Breast Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SWITCH so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 7 |
The trial
ClinicalTrials.gov- Official title
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer：A Prospective, Open-label, Phase 2 Trial
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Advanced Breast Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer (TNBC); HER2-negative Breast Cancer; Breast Cancer
- Interventions
- SHR-A1811; SHR-A1921; SHR-A2009; SHR-A2102; Famitinib; Fat Module Formula for Special Medical Purposes; Trastuzumab (or biosimilar); 9MW2821; Disitamab Vedotin (RC48); Treatment of physician's choice (TPC)
- Arms
- A · Experimental
- B · Experimental
- C · Experimental
- D · Experimental
- E · Experimental
- F · Experimental
- G · Experimental
- H · Experimental
- I · Experimental
- J · Experimental
- Enrollment
- 160 (estimated)
- Primary outcomes
- Objective response rate (ORR)
- Sponsor
- Fudan University
- Start
- Oct 21, 2024
- Primary completion
- Sep 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06649331 · updated Sep 3, 2026